Report Details:
15 Companies Covered
90 Pages
The Rise in the Number of Smokers Expected to Elevate Global Chronic Obstructive Pulmonary Disease Market in 2035
The global chronic obstructive pulmonary disease (COPD) market was valued at USD 22.07 billion in 2024 and is projected to reach USD 37.05 billion by 2035, registering a CAGR of 4.82% between 2025 and 2035.
The market’s expansion is primarily driven by the rising global prevalence of COPD, the adoption of effective combination therapies, and growing public awareness of chronic respiratory disorders.
Increasing healthcare spending in developing nations, coupled with strategic R&D investments by governments and pharmaceutical companies, further strengthens market growth.
While the current therapeutic focus remains on symptom management, the demand for innovative treatment solutions targeting disease pathophysiology is intensifying worldwide.
COPD continues to represent a significant public health challenge and is the third leading cause of death globally, responsible for 3.23 million deaths in 2022, according to the World Health Organization (WHO).
The disease burden remains high across low- and middle-income countries, where nearly 90% of COPD-related deaths among people under 70 occur.
This rising incidence, coupled with the growing geriatric population and environmental risk factors such as smoking and industrial pollution, is expected to sustain market demand over the coming decade.
Segment Insights
By type, the market is segmented into emphysema and chronic bronchitis, with the chronic bronchitis segment holding the largest market share. The dominance of this segment is attributed to the widespread prevalence of bronchitis resulting from cigarette smoking and the increased exposure to industrial pollutants.
In terms of treatment type, drugs remain the leading category, as they are typically the first line of therapy to ease breathing difficulties by widening airways.
The drug segment includes bronchodilator monotherapy, such as Short-Acting Beta2-Agonists (SABAs) and Long-Acting Beta2-Agonists (LABAs), and anti-inflammatory drugs, including oral and inhaled corticosteroids and anti-leukotrienes.
Additionally, oxygen therapy is emerging as the fastest-growing segment due to the rising geriatric population, the increasing preference for home-based treatments, and advancements in respiratory care devices.
Based on end user, hospitals and clinics accounted for the largest market share, driven by the availability of advanced diagnostic and treatment facilities and the rising patient base suffering from chronic respiratory conditions.
The homecare segment is also witnessing growth as portable therapeutic devices become more accessible and affordable.
Regional Insights
Geographically, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America held the largest share, fueled by strong research and development investments, a well-established healthcare infrastructure, and a growing prevalence of chronic respiratory disorders.
The presence of major pharmaceutical companies and ongoing innovation in inhalation therapies further reinforce regional leadership.
Europe accounted for the second-largest share, supported by an advanced healthcare ecosystem and consistent demand for novel respiratory therapies. Germany dominated the European market, while the UK was the fastest-growing market within the region.
The Asia-Pacific region is expected to record the highest CAGR during the forecast period, driven by the growing geriatric population, increased tobacco consumption, and rapid industrialization leading to air pollution.
Countries such as China and India are emerging as key growth hubs, offering substantial opportunities for pharmaceutical and medical device manufacturers to expand their footprint.
Key Players
Major players operating in the global COPD market include AstraZeneca, Abbott Laboratories, Dr. Reddy’s Laboratories Ltd, GlaxoSmithKline, F. Hoffmann-La Roche Ltd, Almirall, Boehringer Ingelheim, Pfizer Inc., Novartis AG, and Astellas Pharma.
These companies are actively engaged in R&D programs and strategic collaborations to develop innovative respiratory drugs and devices.
In June 2022, AstraZeneca announced plans to establish a manufacturing facility in Qingdao, China, for its Breztri aerosol inhalant COPD treatment, which was recently added to China’s National Reimbursement Drug List.
The company also plans to set up a regional headquarters and innovation center for rare diseases in Qingdao. Similarly, Alembic Pharmaceuticals received USFDA approval for its generic version of Arformoterol Tartrate inhalation solution, strengthening its respiratory portfolio.
Key Findings
- The global Chronic Obstructive Pulmonary Disease (COPD) market is projected to grow from USD 22.07 billion in 2024 to USD 37.05 billion by 2035 at a CAGR of 4.82%.
- Growth is fueled by rising COPD prevalence, the dominance of drug-based therapies, and expanding R&D efforts by leading pharmaceutical firms.
- North America remains the largest regional market, while Asia-Pacific is expected to record the fastest growth due to increased smoking rates and industrialization.
- With continuous advancements in inhalation and oxygen-based therapies, the market is set to offer substantial opportunities for innovation and patient-centric respiratory care by 2035.